Julian Baker & Felix Baker
WATCHBaker Brothers Advisors
Legendary biotech investors with extraordinary returns and deep scientific rigor, but SEC settlement and inherently speculative biotech focus limit alignment with our downside-first philosophy.
Healthcare & Biotech Specialists
Score Breakdown
Investment Philosophy & Portfolio Style
Philosophy
Baker Brothers takes a fundamentally research-driven, science-first approach to biotech investing. Felix Baker's PhD in immunology allows the firm to independently evaluate clinical trial data, drug mechanisms, and competitive positioning of biotech companies at a level few investment firms can match. The philosophy centers on identifying companies with genuinely differentiated science and strong drug pipelines, then taking large, concentrated, long-duration positions. They are willing to hold positions for many years through clinical development cycles, which can span 5-10+ years. They combine scientific conviction with large position sizes, often becoming one of the largest shareholders in their portfolio companies. The approach is long-biased with high conviction — closer to venture capital thinking applied to public biotech than traditional hedge fund trading.
Portfolio Style
Highly concentrated — typically 10-20 major positions dominating the portfolio. Extremely long-duration for a biotech fund — they hold positions for years, sometimes a decade or more, through clinical development and commercial launch phases. The portfolio is almost exclusively biotech and pharma, with occasional positions in medtech or diagnostics. They frequently own 5-15% of the companies they invest in, becoming significant shareholders with board-level influence. The portfolio is long-only biased — while they may hedge, the core positions are long, concentrated bets on specific drug pipelines. Position sizes can be enormous — multi-billion dollar stakes in individual companies.
Background
Julian Baker and Felix Baker founded Baker Brothers Advisors in 2000. Julian has a background in finance and previously worked in investment banking and private equity. Felix holds a PhD in immunology from Stanford University, giving the firm genuine scientific expertise in evaluating biotech companies. The firm is based in New York and has grown to manage approximately $20-40 billion in assets (AUM has fluctuated significantly with biotech market cycles). Baker Brothers is widely regarded as one of the most successful biotech-focused investment firms ever, with extraordinary long-term returns. Julian handles the business and investment side while Felix provides deep scientific analysis of drug pipelines and clinical data. The Bakers are among the wealthiest hedge fund managers in the world, with Forbes estimating their combined net worth in the billions.
Track Record
Baker Brothers has one of the best track records in biotech investing history. From 2000 to approximately 2020, the firm generated annualized returns estimated at 20-30%+, dramatically outperforming both the broader market and biotech indices. Their early and large investment in Seattle Genetics (now Seagen) was one of the greatest biotech investments ever made — they were among the largest shareholders for years and the position grew to be worth billions before Pfizer acquired Seagen for $43 billion in 2023. Similarly, their investment in Incyte Corporation was a massive long-term winner, held through the development and approval of Jakafi. However, the firm has also experienced significant drawdowns during biotech bear markets, particularly in 2015-2016 and 2021-2022 when the overall biotech sector declined sharply. The concentrated nature of the portfolio amplifies both gains and losses. In 2023, the firm faced SEC scrutiny and paid a $200 million settlement related to trading practices involving short-term trades in companies where Baker Brothers had board representation, raising questions about information walls. Despite this, the overall long-term track record remains exceptional.
Notable Holdings
Historically, the most notable positions include: Seagen (Seattle Genetics) — held for many years, became a massive winner when Pfizer acquired for $43B; Incyte Corporation — held through the development and commercialization of Jakafi; Acadia Pharmaceuticals; Neurocrine Biosciences; Argenx; Bristol-Myers Squibb (post-Celgene); Ionis Pharmaceuticals. The portfolio typically features mid-to-large cap biotechs with approved or late-stage drugs, plus some earlier-stage positions where the scientific thesis is strong.
Transparency & Integrity
Transparency(Score: 5/10)
Moderate. Baker Brothers files quarterly 13F reports showing public equity holdings, which is the primary window into their portfolio. The Bakers themselves are very private — they rarely give interviews, do not speak at conferences, and do not publicize performance numbers. The firm's website is minimal. The 13F filings provide good visibility into their concentrated public positions, but the firm also has private investments not captured in public filings. The SEC settlement in 2023 revealed some trading practices that were not previously known, suggesting less transparency than ideal regarding potential conflicts of interest.
Integrity(Score: 5/10)
Mixed. On the positive side, the Bakers have built their firm on genuine scientific expertise and long-term conviction investing, which is admirable. They have been significant philanthropists. However, the $200 million SEC settlement in 2023 is a meaningful blemish. The SEC alleged that Baker Brothers made short-term trades in companies where Felix Baker served as a board member, raising concerns about information advantages and conflicts of interest. While the settlement did not involve an admission of wrongdoing (standard in SEC settlements), the size of the penalty ($200M) suggests the regulators viewed the conduct seriously. This is a genuine integrity concern that cannot be dismissed, though it does not appear to involve fraud against investors or fundamental dishonesty in their investment process.
Relevance to Us
Moderate alignment with important caveats. Baker Brothers' concentrated, long-duration, conviction-driven approach is the closest match to our philosophy among healthcare/biotech investors. Their willingness to hold positions for 5-10+ years through development cycles mirrors our patience. The scientific rigor of their analysis is admirable. However, there are significant divergences: (1) biotech investing is inherently speculative — drug development has binary outcomes that create the 'cannot compute floor price' problem in our framework; (2) the SEC settlement raises integrity concerns; (3) biotech companies often have no earnings, no tangible assets, and can go to zero, which conflicts with our 'little chance of losing money' philosophy. Their best ideas in commercial-stage biotech (like Incyte with approved drugs) are more relevant to us than their earlier-stage bets. We could selectively follow their positions in commercial-stage biotechs with proven drugs and growing revenue.